Results from a Phase II Trial of Pembrolizumab in Relapsed/Refractory CLL, Including in Patients with Richter’s Transformation
Ding W et al. PD-1 blockade with pembrolizumab (MK-3475) in relapsed/refractory CLL including Richter transformation: An early efficacy report from a Phase 2 trial (MC1485). Proc ASH 2015;Abstract 834.
Dr Sharman is Director of Research at the Willamette Valley Cancer Institute and Medical Director of Hematology Research at The US Oncology Network in Eugene, Oregon.
|